By participating in the Encore-MDS study, you will be seen by experts who have experience treating MDS patients and receive an investigational drug.*
*RVT-2001 is an investigational drug which may or may not help your MDS. You also could experience side effects. If you move forward, your study doctor will discuss all potential benefits and risks with you.
By enrolling in this study, you will receive:
The main purpose of this study is to determine the safety of the study drug, to find out what is the best dose for patients and to understand better how the study drug impacts anemia in lower risk MDS.
Click See if you may qualify and enter your information to express interest in the study.
Research studies are designed in specific ways to test the study drug for safety and effectiveness. An answer you provided was outside the guidelines for this trial. This does not mean you will not qualify for different research studies.
This study is conducted at research sites throughout the United States, France, Spain, Belgium, Italy, South Korea and Taiwan.
The study drug is taken as a pill by mouth every day. If you are enrolled into the study, your study doctor will tell you how much and how often to take the study medication.
The study drug being tested is RVT-2001, an investigational drug that has not been approved by the FDA or any regulatory agency yet. Because of improper mRNA splicing, people with lower-risk MDS are not able to produce red blood cells the way a healthy individual can.
No, everyone enrolled in this study will be given the study drug. There is no placebo.
You will not have to pay for the study drug, study visits, or for the procedures needed for you to take part in this study. The study sponsor will pay for the costs of the study drug and any tests or procedures required for the study.
You may qualify to be paid back for reasonable travel expenses to and from the clinic for study visits.
Yes. Your participation in the study is completely voluntary and you may leave the study at any time.
If you do not have health insurance, it will still be possible for you to participate in this study.
Hemavant is a clinical-stage biopharmaceutical company dedicated to developing innovative targeted therapeutics to improve the lives of patients with blood disorders and hematological malignancies. To learn more, visit https://hemavant.com.
Our mission to bring better treatments to more people faster starts with you. We help sponsors find patients to participate in their clinical studies. With our focus on rare diseases and expertise in navigating the enrollment process, we're here for you every step of the way. To learn more, visit https://patientwing.com.
Have a question? Call, email us or fill out the form. We're here to help.
